Back to search results

Phase 1 Trial of attIL12-T Cell Therapy for Sarcoma

This study is testing a new immunotherapy called attIL12-T cells, given along with cyclophosphamide (a chemotherapy drug), for people with advanced or metastatic (spread) soft tissue or bone sarcoma. The main goals are to find a safe dose of attIL12-T cells and to see if it can help control the disease. You may be able to join if you are at least 12 years old, have a confirmed soft tissue or bone sarcoma that is advanced or has spread, and have already received at least one other treatment for your sarcoma. The study is looking at how many side effects occur and how well the treatment controls the disease over time. The current status of this study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure adverse events through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05621668

A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma

Active, Not Recruiting
PHASE1Ages 12+InterventionalTreatment
M.D. Anderson Cancer Center
~5 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:CyclophosphamideattIL2-T cells

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To examine the incidence of adverse events.
Measured over through study completion; an average of 1 year.

Conditions

Soft Tissue Sarcoma
Bone Sarcoma

Explore related trials

Bone SarcomaOsteosarcomaSoft Tissue Sarcoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • John Livingston, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

For targeted therapies, at least 4 half-lives or 3 weeks must have elapsed prior to leukapheresis (whichever is shorter). 7. Standard of care anti-cancer therapy will be permitted following leukapheresis but prior to initiation of cyclophosphamide such that:
Total lung capacity \>70% of predicted
DLCO \>60% of predicted 16. Women of childbearing potential (WOCBP) must agree to use method(s) of contraception: at least one highly effective or two effective accepted methods of contraception to avoid conception throughout the study in such a manner that the risk of pregnancy is minimized. Suggested precautions should be used to minimize the risk or pregnancy for at least 1 month before start of therapy, and while women are on study for up to 3 months after T cell infusion. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal 17. Men must be willing and able to use an acceptable method of birth control such as latex condom during the dosing period and for at least 3 months after completion of the study agent administration (T cell infusion) if their sexual partners are WOCBP. 18. Signed Informed Consent and if applicable, pediatric assent

What this trial measures

  • To examine the incidence of adverse events.through study completion; an average of 1 year.

    National Cancer Institute, Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. from screening through the treatment period